Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced a conference call set for March 24, 2022, at 2 p.m. CET to discuss its financial results for the full year ending December 31, 2021. Key executives, including the CEO and CFO, will participate in the call. The event will be accessible via a live webcast and phone dial-in options. Innate Pharma focuses on oncology, developing therapeutic antibodies that leverage the immune system against cancer and maintains collaborations with major biopharmaceutical companies like AstraZeneca and Bristol-Myers Squibb.
- The company is focused on enhancing treatment outcomes with a broad pipeline of potentially first-in-class therapies.
- Successful collaborations with leading biopharmaceutical companies enhance its developmental capabilities.
- None.
Speakers during the call will be:
-
Mondher Mahjoubi , Chief Executive Officer -
Joyson Karakunnel , Executive Vice President, Chief Medical Officer -
Yannis Morel , Executive Vice President, Product Portfolio Strategy & Business Development -
Frédéric Lombard , Senior Vice President, Chief Financial Officer
Details for the Virtual Event
The live webcast will be available at the following link:
https://event.on24.com/wcc/r/3577447/6B0C866D3C3BB7A70F1BAAD02F7320D2.
Participants may also join via telephone using the dial-in details below:
All other locations: +1 929 526 1599
Access code: 834852
This information can also be found on the Investors section of the
About
Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Headquartered in
Learn more about
Information about
ISIN code
|
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005790/en/
Investors and Media
Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Marie Puvieux (
Tel.: +33 981 87 46 72
innate-pharma@atcg-partners.com
Source:
FAQ
What is the date of Innate Pharma's financial results conference call?
What time will Innate Pharma's conference call be held?
Where can I access the webcast for Innate Pharma's conference call?
What financial results will Innate Pharma discuss on the call?